Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia | Zendy

Matthew S. Simon | Zendy; Lars F. Westblade | Zendy; Alexis Dziedziech | Zendy; Joseph E. Visone | Zendy; Richard R. Furman | Zendy; Stephen G. Jenkins | Zendy; Audrey N. Schuetz | Zendy; Laura A. Kirkman | Zendy

Open Access

Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia

Author(s) -

Matthew S. Simon,

Lars F. Westblade,

Alexis Dziedziech,

Joseph E. Visone,

Richard R. Furman,

Stephen G. Jenkins,

Audrey N. Schuetz,

Laura A. Kirkman

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix477

Subject(s) - atovaquone , babesiosis , azithromycin , medicine , chronic lymphocytic leukemia , rituximab , immunology , babesia , leukemia , virology , lymphoma , antibiotics , malaria , microbiology and biotechnology , biology , plasmodium falciparum

Babesiosis treatment failures with standard therapy have been reported, but the molecular mechanisms are not well understood. We describe the emergence of atovaquone and azithromycin resistance associated with mutations in the binding regions of the target proteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research